Latest stories on KRRO
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Korro to Participate in Upcoming Investor Conferences
Business Insider56 · neutralgeneral
Korro to Participate in Upcoming Investor Conferences
GlobeNewswire56 · neutralgeneral
Korro Bio Moves KRRO-121 Into First Human Trials, Raising the Stakes in Rare Disease RNA Editing
TipRanks67 · bullishproduct/pr
Korro Bio, Inc. (KRRO) files 8-K
SEC 8-K50 · neutralgeneral
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Raymond James reiterates Korro Bio stock rating on hyperammonemia outlook
Investing.com Analyst Ratings56 · neutralanalyst
Korro Bio GAAP EPS of -$1.07, revenue of $1.5M
Seeking Alpha28 · bearishearnings
Korro Bio, Inc. (KRRO) files 8-K
SEC 8-K50 · neutralgeneral
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
StockTitan63 · neutralproduct/pr
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KRRO Stock News
StockTitan50 · neutralgeneral
Korro Bio: RNA Editor Plots Way Back After AATD Study Fail - I'm Holding
Seeking Alpha48 · neutralgeneral
Korro Bio Stockholders Approve Directors, Pay and Auditor
TipRanks50 · neutralgeneral
Korro Bio, Inc. (KRRO) files 8-K
SEC 8-K50 · neutralgeneral
Korro to Present at the 2026 Jefferies Global Healthcare Conference | KRRO Stock News
StockTitan56 · neutralgeneral
Korro Bio Advances KRRO-111 for Alpha-1 Deficiency
TipRanks63 · neutralproduct/pr